PHAM QUANG X (CEO and Chairman) sold 12.0% of their position (18.12K shares) of CADRENAL THERAPEUTICS, INC. on the open market
Open‑market sale worth $70.4K — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 3 sales
Filed: 6/16/2026ACC: 0001213900-26-068981
DirectorOfficer10% Owner· CEO and Chairman
Since Jan 2023
-18.12K
Net shares
Net seller
$70.4K
Total sold
3
Open market trades
0B · 3S
3
Total transactions
18.12K disposed
Non-Derivative Transactions3
Common Stock
Direct
Shares
−1.46K
Price / share
$4.12
Trade value
$6.02K
% of position
1.0%
6/11/2026
150.84K→149.38K
Common Stock
Direct
Shares
−13K
Price / share
$3.94
Trade value
$51.20K
% of position
8.7%
6/12/2026
149.38K→136.38K
Common Stock
Direct
Shares
−3.67K
Price / share
$3.58
Trade value
$13.12K
% of position
2.7%
6/15/2026
136.38K→132.72K
Total
Net shares
−18.12K
Net value
-$70.35K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 6/11/2026 | S · Sale | −1.46K | $4.12 | $6.02K | 1.0% | 150.84K | 149.38K |
| Common Stock Direct | 6/12/2026 | S · Sale | −13K | $3.94 | $51.20K | 8.7% | 149.38K | 136.38K |
| Common Stock Direct | 6/15/2026 | S · Sale | −3.67K | $3.58 | $13.12K | 2.7% | 136.38K | 132.72K |
| Total | −18.12K | -$70.35K | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)1
Common Stock
IndirectShares owned200K
Total
200K indirect200K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 200K | Indirect |
| Total | 200K | 200K indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported